Skip to content

G&A at other companies

Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$6.74M+9.8%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$4.6M+2.9%
Savara logo
SavaraSVRA
$15.57M+68.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$26.2M+85.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$6.85M+23.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$11.57M-14.5%

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s G&A?
Upstream Bio, Inc. (UPB) reported G&A of $8.08M in Q1 2026.
How has Upstream Bio, Inc.'s G&A changed year-over-year?
Upstream Bio, Inc.'s G&A increased by 19.2% year-over-year, from $6.78M to $8.08M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.